Breast Biopsy Devices – Market Insights – Global

Despite the short-term challenges posed by the COVID-19 pandemic, the global market for breast biopsy device will grow slowly through 2031. This market will be driven by the increasing awareness of breast cancer screening in emerging markets like China and India, the ongoing shift toward CNB devices in rural areas across different geographies, and the shift toward premium-priced VAB devices in urban areas of developed markets.

This Medtech 360 Report provides comprehensive data and analysis on the state of the breast biopsy device market in the US, Europe, and Asia Pacific region from 2019 to 2031.

The COVID-19 pandemic negatively affected the global breast biopsy device market.

To what extent did the COVID-19 pandemic impact the global breast biopsy device market?

How did the impact of the COVID-19 pandemic differ between segments?

How quickly is the market recovering?

Increasing awareness of breast cancer screening and a shift toward advanced technologies will result in moderate procedure growth in emerging markets such as China and India.

How many procedures are performed annually in these two countries?

Among VAB, CNB, and FNA, which procedure type has the highest penetration in the countries covered?

How will domestic manufacturing policies impact the breast biopsy market in these countries?

VAB will continue to be the most common technique for performing breast biopsies in the large US market, driving global market growth.

How does the reimbursement differ for VAB procedure across the countries covered??

To what extent is VAB being used in Europe and the Asia Pacific region?

Breast biopsy markers represent a significant proportion of overall market revenues.

What factors impact the use of breast biopsy markers?

How will ASPs of breast biopsy markers change over the forecast period?

Table of contents

Breast Biopsy Devices - Market Insights - Global

Nandita Mallya

Aditya Singh is a senior analyst within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at Clarivate, specializing in minimally invasive therapies and emerging technologies markets. Aditya Singh holds Bachelor’s and Master’s degrees in Biotechnology from Amity University, Noida.

Aditya Singh

Contact sales Login to access report

Back to all Medtech Insights reports